

**Guideline:** Colorectal Cancer (CRC) (update) Committee meeting 11

**Date:** 21<sup>st</sup> March 2019 (day 1)

**Location:** RCOG offices, London

**Minutes:** Final

<b>Committee members present:</b>	
Peter Hoskin (Chair)	(Present for notes 1–6)
Justin Davies (Topic Adviser)	(Present for notes 1–6)
Cindy Chew	(Present for notes 1–6)
Julie Hepburn	(Present for notes 1–6)
Jay Bradbury	(Present for notes 1–6)
Richard Roope	(Present for notes 1–6)
Kevin Monahan	(Present for notes 1–4)
Baljit Singh	(Present for notes 1–6)
Charlotte Dawson	(Present for notes 1–6)
Debby Lennard	(Present for notes 1–6)
Vivek Misra	(Present for notes 1-6)
Michael Braun	(Present for notes 1-6)
Manuel Salto-Tellez (Co-optee)	(Present for notes 1–6)
Ratan Verma (Co-optee)	(Present for notes 4-5)

<b>In attendance:</b>		
Maija Kalioinen	NGA Guideline Lead	(Present for notes 1-6)
Palida Teelucknavan	NGA Project Manager	(Present for notes 1-6)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 4-6)
James Hawkins	NGA Senior Health Economist	(Present for notes 4)
Ted Barker	NGA Systematic Reviewer	(Present for notes 1-6)
Rachel Connolly	NGA Business Administrator	(Present for notes 1-4)
Preetpal Doklu	NGA Business Administrator	(Present for notes 1-4)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present for notes 1-6)
Maria Olsen	NICE PhD student (observer)	(Present for notes 1-6)
James Hill	Expert witness	(Present for note 4-4)
Charlene Dixon	NGA Project Manager	(Present for notes 1-4)

<b>Apologies:</b>	
Gemma Burgess	Co-opted Committee Member
Faheez Mohamed	Co-opted Committee Member
Louise Crathorne	NGA Systematic Reviewer

<b>1. Welcome and objectives for the meeting</b>
<p>The Chair welcomed the Committee members and attendees to the 11<sup>th</sup> meeting on Colorectal Cancer guideline (update). The Committee members and attendees introduced themselves.</p> <p>The Chair informed the committee that apologies had been received as noted above.</p> <p>The Chair outlined the objectives of the meeting, which included: NGA End of year finance reminder; preference-sensitive decision tables; review of the evidence for RQ 3.8; expert witness testimony on CREST trial (for RQ 3.8) and drafting recommendations; review of the evidence for RQ 2.1 and drafting recommendations;</p>

research recommendations.

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Role	Declarations of Interest, date declared	Type of interest	Decision taken
Cindy Chew	Committee member (Radiologist)	Early Cancer Detection Test – Lung Cancer Scotland (ECLS) – NCT01925625 (Oncimmune)  Sponsor: NHS Scotland. 12000 patients. I am one of several radiologists across Scotland who read the CTs of the intervention arm of patients with positive blood test.  Declared on: 21/03/2019	Indirect, non-financial	Declare and participate.  Rationale: interest is non-specific.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

## 3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

## 4. Presentations

The Chair introduced Rachel Connolly, NGA Business Administrator, who informed the Committee of the deadline for submitting travel and subsistence expenses claims before the end of the upcoming financial year. The Chair thanked Rachel Connolly.

The Chair introduced Maija Kallioinen, NGA Guideline Lead, who gave a presentation on preference-sensitive decision tables. The Committee then discussed the issues presented in relation to this guideline and thanked Maija Kallioinen for their presentation.

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on Review Question 3.8 'What is the effectiveness of stenting compared with emergency surgery for suspected colorectal cancer causing acute large bowel

obstruction?'. The Chair thanked Nathan Bromham for their presentation.

The Chair introduced James Hill who had just joined the meeting, the principal investigator for CREST trial, who gave an expert witness testimony on the CREST trial in relation to RQ 3.8. James Hill took questions from the Committee. The Chair thanked James Hill for their presentation who then left the meeting.

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on Review Question 2.1 'Which predictive biomarkers should be used in the systemic management of colorectal cancer patients?'. The Committee then discussed the issues presented in relation to this guideline and thanked Nathan Bromham for their presentation.

The Chair introduced Maija Kallioinen, NGA Guideline Lead, who gave a presentation on the research recommendations. The Committee then discussed the issues presented in relation to this guideline and thanked Maija Kallioinen for their presentation.

#### **5. Questions and discussion**

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions. The Committee drafted recommendations based on the evidence heard.

#### **6. Any other business**

There was no other business.

**Date of next meeting:** 22<sup>nd</sup> March 2019

**Location of next meeting:** RCOG, London

**Guideline:** Colorectal Cancer (CRC) (update) Committee meeting 11

**Date:** 22<sup>nd</sup> March 2019 (day 2)

**Location:** RCOG offices, London

**Minutes:** Draft

<b>Committee members present:</b>	
Peter Hoskin (Chair)	(Present for notes 1–5)
Justin Davies (Topic Adviser)	(Present for notes 1–5)
Cindy Chew	(Present for notes 1–5)
Julie Hepburn	(Present for notes 1–5)
Richard Roope	(Present for notes 1–5)
Vivek Misra	(Present for notes 1–5)
Michael Braun	(Present for notes 1–5)
Baljit Singh	(Present for notes 1–5)
Charlotte Dawson	(Present for notes 1–5)
Debby Lennard	(Present for notes 1–5)
Manuel Salto-Tellez (Co-optee)	(Present for notes 1–5)
Stephen Fenwick (Co-optee)	(Present for notes 1–5)

<b>In attendance:</b>		
Maija Kalioinen	NGA Guideline Lead	(Present for notes 1–5)
Palida Teelucknavan	NGA Project Manager	(Present for notes 1–5)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1–5)
James Hawkins	NGA Senior Health Economist	(Present for notes 1–5)
Ted Barker	NGA Systematic Reviewer	(Present for notes 1–5)
Agnesa Mehmeti	NGA Information Scientist	(Present for notes 3-4)
Louise Crathorne	NGA Systematic Reviewer	(Present for notes 3-5)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present for notes 1-5)
Gareth Haman	NICE Editor	(Present for notes 1-5)
Joanna Perkin	NICE Pathways Editor	(Present for note 3-3)
Dion Morton	Expert witness	(Present for note 3-3)

<b>Apologies:</b>	
Kevin Monahan	Committee Member
Jayshree Bradbury	Committee Member
Gemma Burgess	Co-opted Committee Member
Faheez Mohamed	Co-opted Committee Member
Michael Shackcloth	Co-opted Committee Member
Adam Storrow	NICE Business Analyst

### **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the second day of the 11<sup>th</sup> meeting on Colorectal Cancer guideline (update). The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included: revisiting the health economic evidence for RQ 4.3b; the NICE Pathway; expert witness testimony on

FOXTROT trial (for RQ 3.3) and reviewing drafted recommendations; reviewing the guideline as a whole and reviewing all draft recommendations and rationale and impact sections; yimeline and next steps.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Role	Declarations of Interest, date declared	Type of interest	Decision taken
Manuel Salto-Tellez	Co-opted committee member (Molecular Pathologist)	Part of the S-CORT research programme, which will eventually analyse samples from the FOXTROT trial. No such samples have been analysed in the laboratory to date.  Declared on 22/03/2019	Direct, non-financial	Declare and participate. Rationale: FOXTROT trial relates to review question 3.3 on neoadjuvant therapy on colon cancer but the programme is not specific to the review question.

It was also noted that MB declared an original interest in Jan 2018 as the local principal investigator for FOXTROT. However, a decision was made that MB can participate in the discussion because as a local principal investigator MB did not receive funding or was not involved in the planning of the trial, or the analysis and write up of the results.

The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

**3. Presentations**

The Chair introduced James Hawkins, NGA Senior Health Economist, who gave a presentation on cost-effectiveness of treatments of metastatic colorectal cancer in the liver (RQ 4.3b). The Committee then discussed the issues presented in relation to this guideline and thanked James for their presentation.

The Chair introduced Joanna Perkin, NICE Pathways Editor, who gave a presentation

on the NICE Pathway for Colorectal Cancer. The Committee then discussed the issues presented in relation to this guideline and thanked Joanna Perkin for their presentation.

The Chair introduced Dion Morton who had just joined the meeting, the principal investigator for FOXTROT trial, who gave an expert witness testimony on the FOXTROT trial in relation to RQ 3.3. Dion Morton took questions from the Committee. The Chair thanked Dion Morton for their presentation who then left the meeting.

#### **4. Questions and discussion**

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions. The Committee drafted recommendations based on the evidence heard.

The Committee reviewed the full guideline and agreed on the sections, sequencing of the recommendations and reviewed the NICE Editor's comments.

#### **5. Any other business**

There was no other business.

**Date of next meeting:** 24<sup>th</sup> April 2019

**Location of next meeting:** RCOG, London